Table of Contents Author Guidelines Submit a Manuscript
International Journal of Pediatrics
Volume 2010, Article ID 846098, 6 pages
Research Article

Insulin Sensitivity, Serum Lipids, and Systemic Inflammatory Markers in School-Aged Obese and Nonobese Children

1Department of Pediatrics, Comer Children's Hospital, The University of Chicago, Suite K-160, 5721, Maryland Avenue, MC 8000, Chicago, IL 60637, USA
2Division of Sleep and Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada M5G 1X8
3Pediatric Sleep Unit, Division of Neurophysiology, Department of Neurology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
4Dana Children's Hospital, Tel-Aviv University School of Medicine, Tel-Aviv 64239, Israel

Received 29 June 2010; Revised 31 October 2010; Accepted 24 December 2010

Academic Editor: Tai Fai Fok

Copyright © 2010 Jinkwan Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The impact of obesity as a systemic low-grade inflammatory process has only partially been explored. To this effect, 704 community-based school-aged children (354 obese children and 350 age-, gender-, and ethnicity-matched controls) were recruited and underwent assessment of plasma levels of fasting insulin and glucose, lipids, and a variety of proinflammatory mediators that are associated with cardiometabolic dysfunction. Obese children were at higher risk for abnormal HOMA and cholesterol levels. Furthermore, BMI z score, HOMA, and LDL/HDL ratio strongly correlated with levels of certain inflammatory mediators. Taken together, obesity in children is not only associated with insulin resistance and hyperlipidemia, but is accompanied by increased, yet variable, expression of markers of systemic inflammation. Future community-based intervention and phenotype correlational studies on childhood obesity will require inclusion of expanded panels of inflammatory biomarkers to provide a comprehensive assessment of risk on specific obesity-related morbidities.